CommercializationRenovoRx is actively commercializing its FDA-cleared RenovoCath as a standalone proprietary medical device, marking a significant milestone for the company.
Market PotentialRenovoRx has a significant market potential with its focus on Locally Advanced Pancreatic Cancer, one of the deadliest cancers with very poor prognosis and outcomes.
ValuationThe current valuation is considered attractive, with a raised 12-month price target to $9.00, representing significant upside from the current share price.